Journals
Publish with us
Publishing partnerships
About us
Blog
Advances in Urology
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Advances in Urology
/
2013
/
Article
/
Tab 1
/
Research Article
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
Table 1
Patient demographics and clinical characteristics.
Neoadjuvant chemotherapy
value
No
(%)
Yes
(%)
Gender
0.87
Male
70 (76%)
66 (76%)
Female
21 (24%)
21 (24%)
Age
0.02
<60
21 (23%)
32 (37%)
60–69
33 (36%)
35 (40%)
>70
37 (41%)
20 (23%)
Race
0.99
Caucasian
79 (89%)
75 (88%)
Other
10 (11%)
10 (12%)
Complete TURBT
0.28
Yes
32 (35%)
39 (46%)
No
53 (58%)
43 (51%)
Unknown
6 (7%)
3 (4%)
Cardiac disease
0.13
Yes
23 (25%)
14 (16%)
No
68 (75%)
73 (84%)
Creatinine
0.49
≤1.0
47 (53%)
51 (59%)
>1.0
41 (47%)
36 (41%)